• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications don't work for a majority of people who are depressed. A customized treatment could be the solution.

Cue is an intervention platform that converts passively acquired sensor data from smartphones into customized micro-interventions to improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to understand their feature predictors and reveal distinct features that deterministically change mood with time.

Predictors of Mood

Depression is one of the most prevalent causes of mental illness.1 However, only about half of those suffering from the disorder receive treatment1. To improve the outcomes, doctors must be able to recognize and treat patients who have the highest chance of responding to certain treatments.

The ability to tailor depression treatments is one way to do this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit the most from specific treatments. They use sensors on mobile phones as well as a voice assistant that incorporates artificial intelligence, and other digital tools. Two grants were awarded that total over $10 million, they will make use of these tools to identify biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

The majority of research done to the present has been focused on sociodemographic and clinical characteristics. These include factors that affect the demographics such as age, gender and education, clinical characteristics such as the severity of symptoms and comorbidities and biological markers like neuroimaging and genetic variation.

While many of these aspects can be predicted by the data in medical records, few studies have utilized longitudinal data to determine the factors that influence mood in people. Few also take into account the fact that moods vary significantly between individuals. Therefore, it is crucial to develop methods which permit the determination and quantification of the personal differences between mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to identify patterns of behavior and emotions that are unique to each person.

In addition to these modalities the team also developed a machine-learning algorithm to model the changing factors that determine a person's depressed mood. The algorithm combines these personal differences into a unique "digital phenotype" for each participant.

The digital phenotype was associated with CAT-DI scores, a psychometrically validated symptom severity scale. The correlation was not strong however (Pearson r = 0,08; P-value adjusted for BH = 3.55 10 03) and varied widely between individuals.

Predictors of Symptoms

Depression is the most common cause of disability around the world, but it is often misdiagnosed and untreated2. In addition an absence of effective interventions and stigma associated with depressive disorders stop many individuals from seeking help.

To aid in the development of a personalized treatment plan in order to provide a more personalized treatment, identifying factors that predict the severity of symptoms is crucial. However, the methods used to predict symptoms depend on the clinical interview which has poor reliability and only detects a small variety of characteristics associated with herbal depression treatments.2

Using machine learning to blend continuous digital behavioral phenotypes captured by sensors on smartphones and an online mental health tracker (the Computerized Adaptive Testing Depression Inventory, CAT-DI) together with other predictors of severity of symptoms could improve the accuracy of diagnosis and the effectiveness of treatment for psychotic depression treatment. Digital phenotypes can provide continuous, high-resolution measurements as well as capture a wide variety of distinct behaviors and patterns that are difficult to record with interviews.

The study comprised University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA depression treatment cbt Grand Challenge. Participants were sent online for support or to clinical treatment according to the degree of their depression. Those with a score on the CAT DI of 35 65 were assigned to online support with an online peer coach, whereas those with a score of 75 patients were referred to psychotherapy in person.

Participants were asked a series of questions at the beginning of the study regarding their psychosocial and demographic characteristics as well as their socioeconomic status. These included sex, age education, work, and financial status; if they were divorced, married or single; their current suicidal ideation, intent or attempts; as well as the frequency with which they drank alcohol. The CAT-DI was used for assessing the severity of depression-related symptoms on a scale ranging from 0-100. The CAT-DI tests were conducted every other week for participants who received online support and weekly for those receiving in-person support.

Predictors of Treatment Response

Research is focusing on personalization of treatment for depression. Many studies are aimed at finding predictors, which can help clinicians identify the most effective medications for each person. Pharmacogenetics, for instance, is a method of identifying genetic variations that affect the way that our bodies process drugs. This allows doctors select medications that will likely work best for every patient, minimizing time and effort spent on trial-and error treatments and avoid any negative side negative effects.

Another promising approach is to develop prediction models that combine information from clinical studies and neural imaging data. These models can then be used to identify the most appropriate combination of variables predictive of a particular outcome, like whether or not a particular medication is likely to improve symptoms and mood. These models can be used to predict the response of a patient to a treatment, which will help doctors maximize the effectiveness.

A new era of research employs machine learning techniques, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables to improve predictive accuracy. These models have shown to be useful for forecasting treatment outcomes, such as the response to antidepressants. These methods are becoming more popular in psychiatry, and are likely to become the standard of future treatment.

Research into the underlying causes of depression continues, in addition to ML-based predictive models. Recent research suggests that the disorder is linked with neurodegeneration in particular circuits. This suggests that individualized depression shock treatment for depression will be based on targeted treatments that target these circuits in order to restore normal functioning.

Internet-based-based therapies can be a way to achieve this. They can offer a more tailored and individualized experience for patients. A study showed that an internet-based program helped improve symptoms and provided a better quality of life for MDD patients. A controlled study that was randomized to a customized treatment for depression revealed that a substantial percentage of patients experienced sustained improvement and fewer side consequences.

Predictors of side effects

In the treatment of depression, a major challenge is predicting and determining the antidepressant that will cause minimal or zero negative side negative effects. Many patients experience a trial-and-error method, involving several medications prescribed before finding one that is effective and tolerable. Pharmacogenetics provides an exciting new way to take an efficient and specific method of selecting antidepressant therapies.

A variety of predictors are available to determine which antidepressant to prescribe, such as gene variants, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and the presence of comorbidities. However, identifying the most reliable and valid predictors for a particular treatment is likely to require controlled, randomized trials with much larger samples than those typically enrolled in clinical trials. This is due to the fact that it can be more difficult to determine moderators or interactions in trials that comprise only one episode per person instead of multiple episodes over a long period of time.

Furthermore the prediction of a patient's response will likely require information about comorbidities, symptom profiles and the patient's personal perception of the effectiveness and tolerability. There are currently only a few easily assessable sociodemographic variables and clinical variables are reliably related to response to MDD. These include gender, age, race/ethnicity, SES, BMI and the presence of alexithymia.

The application of pharmacogenetics to depression treatment plan cbt treatment is still in its infancy and there are many hurdles to overcome. First it is necessary to have a clear understanding of the genetic mechanisms is essential, as is a clear definition of what constitutes a reliable predictor for treatment response. In addition, ethical concerns, such as privacy and the ethical use of personal genetic information must be considered carefully. In the long-term pharmacogenetics can provide an opportunity to reduce the stigma that surrounds mental health ketamine Treatment for Depression and improve the outcomes of those suffering with depression. However, as with any other psychiatric treatment, careful consideration and planning is essential. At present, it's ideal to offer patients an array of depression medications that work and encourage them to speak openly with their doctor.